Hyderabad: Degrowth in its US formulations business dragged down Aurobindo Pharma's consolidated net profits for the third ...

Aurobindo Pharma on Thursday reported a 10 per cent year-on-year (Y-o-Y) drop in consolidated profit after tax (PAT) for the ...

Aurobindo Pharma reported a 10% YoY decline in net profit to Rs 846 crore for Q3FY25, mainly due to a decrease in US sales.

Telangana: Aurobindo Pharma has announced that the Company will be investing Rs.10.40 crores to acquire 26 percent equity and ...

The Hyderabad-based bulk and generic drug maker's net profit fell 9.7% year-on-year to Rs 846 crore in the quarter ended Dec.

Indian drugmaker Aurobindo Pharma reported a lower third-quarter profit on Thursday, as a spike in expenses more than offset strong demand for its generic drugs.

Aurobindo Pharma’s Q3 net profit declined 10% YoY to Rs 846 crore, despite record revenue of Rs 7,979 crore. US sales ...

Aurobindo Pharma's net profit fell 10% to Rs 846 crore in Q3 FY25, while revenue rose to Rs 7,979 crore. The company attributes this to volume growth and new launches.

Ahead of earnings announcement, shares of Aurobindo Pharma ended the trading session flat at ₹1,184.50 apiece on the BSE, ...

Bonus Mar 07, 2000 Apr 01, 2000 Feb 22, 2000 Bonus Ratio: 1 share(s) for every 1 shares held Bonus Oct 26, 1998 Nov 19, 1998 Oct 08, 1998 Bonus Ratio: 1 share(s) for every 1 shares held Aurobindo ...

Aurobindo Pharma ordered to pay over ₹155 crore in GST, interest, and penalty under Central Goods and Services Tax Act.